Cargando…

A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months

This first in human study was designed as an open label clinical trial to assess the safety and immunogenicity of SIIPL DTwP-HepB-IPV-Hib (Hexavalent) combination vaccine in healthy toddlers, aged 16–24 months. A total of 24 healthy toddlers were administered a 0.5 ml single dose of SIIPL DTwP-HepB-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Hitt, Lalwani, Sanjay, Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Palkar, Sonali, Hanumante, Neeta, Gokhale, Shilpa, Ks, Jaganathan, Kumar, Rakesh, Sharma, Inderjit, Gairola, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Licensed Vaccines – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746440/ https://www.ncbi.nlm.nih.gov/pubmed/36412272 http://dx.doi.org/10.1080/21645515.2022.2146435

Ejemplares similares

Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in India
por: Mangarule, S., et al.
Publicado: (2022)

Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India
por: Mangarule, S, et al.
Publicado: (2022)

Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants–A randomized study
por: Aloysia D’Cor, Naveena, et al.
Publicado: (2023)

A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India
por: Sharma, Hitt, et al.
Publicado: (2023)

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
por: George, Marina, et al.
Publicado: (2023)

Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand
por: Sanchez, Leilani, et al.
Publicado: (2023)

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously
por: Ahonen, Anitta, et al.
Publicado: (2022)

Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study
por: Mangarule, S, et al.
Publicado: (2022)

Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants
por: Gandhi, Dulari J., et al.
Publicado: (2015)

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
por: Zhang, Yuntao, et al.
Publicado: (2022)

A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts
por: Arora, Narendra Kumar, et al.
Publicado: (2020)

DTaP-IPV-HepB-Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants
por: Wilck, Marissa B., et al.
Publicado: (2020)

Immunological Links to Nonspecific Effects of DTwP and BCG Vaccines on Infant Mortality
por: Claesson, Mogens Helweg
Publicado: (2011)

Correction to: DTaP‑IPV‑HepB‑Hib Vaccine (Hexyon(®)): An Updated Review of its Use in Primary and Booster Vaccination
por: Syed, Yahiya Y.
Publicado: (2019)

DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18–24 months old
por: Gunardi, Hartono, et al.
Publicado: (2018)

The progress of postapproval clinical studies on Sabin IPV
por: Shi, Li, et al.
Publicado: (2021)

Whole-cell pertussis vaccine (DTwP) has no influence on allergic diseases and atopic sensitization in children
por: Mrozek-Budzyn, Dorota, et al.
Publicado: (2018)

Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review
por: Knuf, Markus, et al.
Publicado: (2023)

2702. Infants Vaccinated with a Fully-Liquid DTaP-IPV-Hib-HepB Vaccine Are Protected During the High-Risk Period for Haemophilus Influenzae Type B Disease
por: Wilck, Marissa B, et al.
Publicado: (2019)

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age
por: Silfverdal, Sven A, et al.
Publicado: (2014)

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials
por: Kelly, Sarah, et al.
Publicado: (2023)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
por: Lalwani, Sanjay K., et al.
Publicado: (2016)

A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults
por: Sharma, Hitt, et al.
Publicado: (2023)

The Immunogenicity and Safety of a Combined DTaP-IPV//Hib Vaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: a Randomized Clinical Trial in South Korean Infants
por: Kang, Jin Han, et al.
Publicado: (2016)

Clinical study of safety and immunogenicity of pentavalent DTP-HB-Hib vaccine administered by disposable-syringe jet injector in India
por: Bavdekar, Ashish, et al.
Publicado: (2019)

Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception
por: Martini Rodrigues, Camila Cristina, et al.
Publicado: (2022)

Lasting immune memory against hepatitis B in 12–13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Behre, Ulrich, et al.
Publicado: (2016)

Long-term antibody persistence against hepatitis B in adolescents 14–15-years of age vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in infancy
por: Schwarz, Tino F., et al.
Publicado: (2018)

Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy
por: Costantino, Claudio, et al.
Publicado: (2022)

1112 A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants
por: Marshall, Gary S., et al.
Publicado: (2014)

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa
por: Vesikari, Timo, et al.
Publicado: (2017)

ASVAC2022 : 8(th) Asian Vaccine Conference
por: Galagoda, Geethani C. S., et al.
Publicado: (2023)

Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
por: Van den Steen, Peter, et al.
Publicado: (2023)

Mumps-specific antibody persistence in children aged 3–7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China
por: Sun, Jinfang, et al.
Publicado: (2023)

Public health impact of herpes zoster vaccination on older adults in Hong Kong
por: Chan, Paul K. S., et al.
Publicado: (2023)

Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial
por: Sun, Dapeng, et al.
Publicado: (2023)

Trends in research related to vaccine and cancer prevention from 1992 to 2022: A 30-years bibliometric analysis
por: Zhang, Luofei, et al.
Publicado: (2023)

Seroprevalence rates in children aged 3-6 years after implementing a two-dose varicella vaccination: A observational study
por: Zhang, Zhuoyu, et al.
Publicado: (2023)

Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella–zoster virus
por: Hwang, Ji-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gji2mb2q2sn2ejq2i859cjuj61